deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT03813836

Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC (POPPY)

A Phase II Trial to Assess the Efficacy and Safety Profile of Pembrolizumab in Patients With Performance Status 2 With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Sponsor: Merck Sharp & Dohme LLC

Conditions Metastatic Head and Neck Squamous Cell Carcinoma Recurrent Head and Neck Squamous Cell Carcinoma
Interventions Pembrolizumab
Updated 14 times since 2019 Last updated: Nov 8, 2024 Started: Jul 5, 2019 Primary completion: Jan 10, 2024 Completion: Jan 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03813836, this PHASE2 trial focuses on Metastatic Head and Neck Squamous Cell Carcinoma and Recurrent Head and Neck Squamous Cell Carcinoma and remains ongoing. Sponsored by Merck Sharp & Dohme LLC, it has been updated 14 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Aug 2019 · 3 months · monthly snapshot~Aug 2019 – ~Apr 2020 · 8 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshot~Nov 2021 – ~Jun 2022 · 7 months · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Jul 2023 · 12 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Sep 2025 · 9 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Dec 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Sep 2024 — Dec 2024 [monthly]

    Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  5. Jul 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

▶ Show 9 earlier versions

  1. Jul 2022 — Jul 2023 [monthly]

    Recruiting PHASE2

  2. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  3. Nov 2021 — Jun 2022 [monthly]

    Recruiting PHASE2

  4. Jan 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  5. Apr 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  6. Aug 2019 — Apr 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. May 2019 — Aug 2019 [monthly]

    Not Yet Recruiting PHASE2

  8. Apr 2019 — May 2019 [monthly]

    Not Yet Recruiting PHASE2

  9. Feb 2019 — Apr 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
  • University College, London
Data source: University College, London

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United Kingdom , Bristol, United Kingdom , Edinburgh, United Kingdom , Ipswich, United Kingdom , London, United Kingdom , Manchester, United Kingdom , Metropolitan Borough of Wirral, United Kingdom , Northwood, United Kingdom , Romford, United Kingdom , Taunton, United Kingdom and 1 more location